Taro Pharmaceutical Industries Ltd's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Taro Pharmaceutical Industries Ltd's ROA in the fourth quarter of 2023?
Taro Pharmaceutical Industries Ltd achieved a return on average assets (ROA) of 1.2 % in its fourth quarter of 2023, which is below Taro Pharmaceutical Industries Ltd's average return on assets, which stands at 13.76%.

ROA fell compared to the third quarter of 2023, despite the net income growth of % from the third quarter of 2023.

However, within the Healthcare sector 199 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2023 from to 2387.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2023) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Mar 31 2022) IV. Quarter
Y / Y Total Assets Change	23.22 %	-11.22 %	-11.22 %	-15.14 %	-21.94 %
Y / Y Net Income Change	-56.33 %	-	-	-	-
Net Income (TTM) in million	25	58	58	58	58
Return On Assets (TTM)	1.2 %	2.9 %	2.8 %	2.71 %	2.6 %
TARO's Total Ranking	# 2387	#	#	#	# 2071
Total Assets (TTM) in million	2,137	2,137	2,137	2,042	1,734
Seq. Total Assets Change	0 %	0 %	4.62 %	17.78 %	-27.95 %
Seq. Net Income Change	-	-	-	-	-

TARO's 5 Years Annual ROA >> Back to TARO Management Effectiveness >> Compare TARO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 74
Sector	# 200
Overall	# 2347

Return On Assets Statistics
High	Average	Low
31.16 %	13.76 %	-16.65 %
(Mar 31 2013)		(Mar 31 2021)

Financial Statements
Taro Pharmaceutical Industries Ltd's Assets	$ 2,137 million	TARO's Balance sheet
Taro Pharmaceutical Industries Ltd's Income	$ 25 million	Quarterly TARO's Income Statement
TARO's Income by Division		See TARO's Income by Division

Annual Return On Assets	(Mar 31 2023) FY 2023	(Mar 31 2022) FY 2022	(Mar 31 2021) FY 2021	(Mar 31 2020) FY 2020	(Mar 31 2019) FY 2019
Y / Y Total Assets Change	4.69 %	-16.61 %	-26.07 %	-0.32 %	1.26 %
Total Assets in million	1,939	1,853	2,222	3,005	3,015
Y / Y Net Income Change	-56.33 %	-	-	-13.32 %	34.29 %
Net Income in million	25	58	-401	245	282
Annual Return On Assets	1.31 %	3.15 %	-18.04 %	8.14 %	9.36 %

TARO's 5 Years Annual ROA >> Back to TARO Management Effectiveness >> Compare TARO ROA to its Competitors

Comment on TARO's ROA in the fiscal year ending 2023

In the fiscal year 2023 Taro Pharmaceutical Industries Ltd's ROA decreased compared to previous year to 1.31 %, due to deterioration of net income -56.33 % to $25.45 million, from $58.27 million a year ago, as TARO's assets were $1,939.50 million.

More Return On Assets Ratios
TARO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TARO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TARO's Competitors
Subscribers only: Roa for Taro Pharmaceutical Industries Ltd's Suppliers
Subscribers only: Return On Assets for TARO's Customers

You may also want to know
TARO's Roi	TARO's Inventory Turnover Ratio	TARO's Growth Rates	TARO's Dividend Comparisons
	TARO's Profitability Ratios	TARO's Asset Turnover Ratio	TARO's Dividend Growth
TARO's Roe	TARO's Valuation Ratios	TARO's Financial Strength Ratios	TARO's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2023, within Healthcare Sector	ROA
Envista Holdings Corporation	3.26 %
Celularity Inc	3.20 %
Skinhealth Systems Inc	3.11 %
American Oncology Network Inc	3.04 %
Becton Dickinson And Company	3.03 %
Phibro Animal Health Corporation	3.03 %
Supernus Pharmaceuticals inc	3.02 %
Select Medical Holdings Corp	2.98 %
Organogenesis Holdings Inc	2.98 %
Neurocrine Biosciences Inc	2.88 %
American Shared Hospital Services	2.88 %
Boston Scientific Corporation	2.79 %
Ethema Health Corporation	2.78 %
Hh and l Acquisition Co	2.76 %
Northview Acquisition Corp	2.63 %
Viveon Health Acquisition Corp	2.61 %
Ligand Pharmaceuticals Incorporated	2.59 %
Avanos Medical Inc	2.57 %
Vanda Pharmaceuticals Inc	2.54 %
The Cooper Companies Inc	2.50 %
Precision Optics Corporation Inc	2.48 %
Integer Holdings Corporation	2.44 %
Puma Biotechnology Inc	2.37 %
Takeda Pharmaceutical Company Limited	2.27 %
Apeiron Capital Investment Corp	2.24 %
Zimmer Biomet Holdings Inc	2.12 %
Aspire Biopharma Holdings Inc	2.10 %
Tevogen Bio Holdings Inc	2.08 %
Schrodinger Inc	2.00 %
Blueriver Acquisition Corp	1.98 %

Date modified: 2023-06-30T08:25:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.